Omega-3 Yağ Asitleri için Telogen Effluvium
B Kanıt Bunu büyük ölçüde tutarlı sonuçlarla en az bir randomize çalışma desteklemektedir.11 çalışmaya, toplam 317 katılımcıyla dayanmaktadır. 8/11 çalışma olumlu etkiler göstermektedir.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dtelogen\u002Deffluvium';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Sonuç
Moderate evidence suggests that omega-3 fatty acids may help support hair recovery in telogen effluvium, though the research base is limited and they are usually studied alongside other nutrients.
- 8 out of 11 studies show positive effects, but total sample size is small (317 participants)
- Often studied as part of multi-nutrient supplement formulations
- No large-scale RCTs specifically for omega-3 and telogen effluvium
- May support recovery through anti-inflammatory and nutritional mechanisms
Key Study Findings
review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5
vs: Placebo
Etki: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2%
None
narrative review
Herbal Remedies for Hair Loss: A Review of Efficacy and Safety.
Dose: varies by remedy and study
vs: Placebo
Etki: None
None
scoping_review
n=16
A Scoping Review of Exosome Delivery Applications in Hair Loss.
Dose: variable; exosomes predominantly from mesenchymal stem cells (MSCs)
vs: Placebo
Etki: None
None
review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri
vs: Placebo
Etki: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo
None
Cohort
n=200
Open-label
Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life …
Dose: high dose elemental iron (dose unspecified)
vs: Placebo
Etki: Patients with baseline ferritin ≥50 ng/ml mostly 'very satisfied'; patients with ferritin <50 ng/ml
None
clinical trial (open-label)
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with …
Dose: None
vs: Placebo
Etki: None
None
Key Statistics
11
Çalışmalar
317
Katılımcılar
↑
Positive
B
Derece
Referenced Papers
American journal of …
2026
1 atıf
Cureus
2025
7 atıf
Skin appendage disorders
2025
7 atıf
Journal of cosmetic …
2025
Indian journal of …
2024
4 atıf
Journal of cosmetic …
2023
6 atıf
Journal of cosmetic …
2022
30 atıf
NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India.
Observational
Journal of cosmetic …
2019
25 atıf
Acta dermatovenerologica Croatica …
2016
6 atıf
Georgian medical news
2007
Therapeutische Umschau. Revue …
2002
4 atıf
Dermatologic clinics
1993
38 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 250-500 mg EPA+DHA/day
- hairloss:
- 1,000-2,000 mg/day
Üst sınır: 3,000 mg/day EPA+DHA
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 | -- | Positive | -- |
| varies by remedy and study | -- | Positive | -- |
| variable; exosomes predominantly from mesenchymal stem cells (MSCs) | -- | Positive | 16 |
| Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri | -- | Positive | -- |
| high dose elemental iron (dose unspecified) | -- | Positive | 200 |
| None | -- | Positive | -- |
| None | -- | Neutral | 100 |
| psychiatric and dermatological management | -- | Neutral | 1 |
En iyi alım zamanı: With meals containing fat for optimal absorption; split doses if over 1,000 mg
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Fishy aftertaste or burping
- ⚠ Mild gastrointestinal upset (nausea, diarrhea)
- ⚠ Possible increased bleeding time at high doses
- ⚠ Unpleasant body odor at very high doses
Bilinen Etkileşimler
- ● Anticoagulants (warfarin) and antiplatelet drugs (may increase bleeding risk)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (reduces omega-3 absorption)
Tolere edilebilir üst alım: 3,000 mg/day EPA+DHA
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Omega-3 Yağ Asitleri help with Telogen Effluvium?
Based on 11 studies with 317 participants, there is moderate evidence from clinical studies that Omega-3 Yağ Asitleri may support Telogen Effluvium management. Our evidence grade is B (Good Evidence).
How much Omega-3 Yağ Asitleri should I take for Telogen Effluvium?
Studies have used various dosages. A commonly studied range is 250-500 mg EPA+DHA/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Yağ Asitleri?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal upset (nausea, diarrhea), Possible increased bleeding time at high doses, Unpleasant body odor at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Yağ Asitleri and Telogen Effluvium?
We rate the evidence as Grade B (Good Evidence). This rating is based on 11 peer-reviewed studies with 317 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Telogen Effluvium
Omega-3 Yağ Asitleri diğer sağlık durumları için
References
- [1] Michael M Ong et al.. Am J Clin Dermatol. 2026. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. doi:10.1007/s40257-025-00990-4 PubMed
- [2] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
- [3] Azhar Ahmed et al.. Skin Appendage Disord. 2025. Herbal Remedies for Hair Loss: A Review of Efficacy and Safety. doi:10.1159/000542876 PubMed
- [4] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
- [5] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
- [6] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
- [7] Kabir Sardana et al.. J Cosmet Dermatol. 2022. Role of nutritional supplements in selected dermatological disorders: A review. doi:10.1111/jocd.14436 PubMed
- [8] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
- [9] Jana Zímová et al.. Acta Dermatovenerol Croat. 2016. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. PubMed
- [10] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
- [11] R M Trüeb. Ther Umsch. 2002. [Diffuse hair loss in women]. doi:10.1024/0040-5930.59.5.217 PubMed
- [12] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.